Every 8-K that Kymera Therapeutics, Inc. (KYMR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KYMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYMR filings page.
Kymera Therapeutics reported second-quarter 2026 results, with collaboration revenue of $65.0 million consisting of a $45 million option exercise fee from Gilead and a $20 million milestone from Sanofi. Research and development expenses were $119.5 million and general and administrative expenses were $21.1 million, resulting in a net loss of $61.2 million, or $0.62 per share. Cash, cash equivalents and investments totaled $1.5 billion as of June 30, 2026, and the company expects this cash balance to provide a runway into 2029.
Kymera also outlined rapid progress in its immunology pipeline. Enrollment in the KT‑621 BROADEN2 Phase 2b atopic dermatitis trial was completed nearly six months early, with topline data now expected by year‑end 2026 and Phase 3 trials planned by mid‑2027. The KT‑621 BREADTH Phase 2b asthma trial is ongoing with data expected in late 2027, KT‑579 Phase 1 data are anticipated in the fourth quarter of 2026, and partnered programs KT‑485 with Sanofi and KT‑200 with Gilead advanced into early clinical and IND‑enabling stages.
Kymera Therapeutics, Inc. announced a leadership transition in its Chief Medical Officer role. Jared Gollob, M.D., submitted his resignation as CMO on July 27, 2026, citing personal reasons and indicating it was not due to any disagreement with the company’s practices or policies. He will continue serving as an advisor through December 31, 2026.
Effective July 27, 2026, Terence Rooney, M.D., a veteran immunology drug development leader with experience at Johnson & Johnson, Eli Lilly and Roche, becomes CMO and will lead global clinical development strategy for Kymera’s oral immunology portfolio. The company furnished a press release as Exhibit 99.1 describing his background and Dr. Gollob’s eight years of leadership.
Kymera Therapeutics reported that it has completed enrollment in its global BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis. Because enrollment finished nearly six months ahead of plan, the company now expects topline Phase 2b data by year-end 2026 instead of mid-2027. Subject to regulatory discussions, Kymera plans to start Phase 3 trials in atopic dermatitis by mid-2027. KT-621 is also being studied in the BREADTH Phase 2b asthma trial, with data expected in late 2027, and previously received Fast Track designation from the FDA for atopic dermatitis and eosinophilic asthma.
Kymera Therapeutics, Inc. reported the results of its Annual Meeting of Shareholders held on June 24, 2026. Shareholders elected four Class III directors — Bruce Booth, Nello Mainolfi, John Maraganore and Elena Ridloff — each to serve three-year terms ending at the 2029 annual meeting.
Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 74,903,687 votes for and 2,462,732 against. In addition, shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 79,043,801 votes for and minimal opposition.
Kymera Therapeutics, Inc. reported that Chief Operating Officer Jeremy Chadwick has communicated his intention to retire and submitted his resignation as COO on June 5, 2026. He will remain an employee of the company as an advisor until November 2026 to support the transition.
The company states that Mr. Chadwick resigned for personal reasons and that his decision was not the result of any disagreement with Kymera’s practices or policies. The filing is framed as an orderly leadership change with continued advisory involvement over several months.
Kymera Therapeutics reported first quarter 2026 results, highlighting pipeline progress and stronger collaboration revenue. Collaboration revenue was $34.4 million, up from $22.1 million a year earlier, driven by its partnership with Gilead Sciences.
Research and development expenses rose to $98.2 million and general and administrative expenses to $20.4 million, leading to a net loss of $69.2 million, compared with $65.6 million in the prior-year quarter. Kymera ended March 31, 2026 with $1.55 billion in cash, cash equivalents and investments and expects this balance to fund operations into 2029 while advancing KT-621, KT-579 and partnered programs including KT-200 and KT-485/SAR447971.
Kymera Therapeutics, Inc. reported that its Board of Directors approved an immediate amendment to the company’s Second Amended and Restated Bylaws. The change designates the federal district courts of the United States as the exclusive forum for any complaints asserting causes of action under the Securities Act of 1933 or the Securities Exchange Act of 1934, and related regulations, unless the company agrees in writing to a different forum.
The amendment aligns the company’s bylaws with recent changes to the Delaware General Corporation Law regarding forum selection provisions. The full text of the amendment is provided as an exhibit to the report for shareholders and other stakeholders who want to review the precise language.
Kymera Therapeutics, Inc. established an at-the-market stock offering program allowing it to sell up to $500,000,000 of common shares through TD Securities (USA) LLC, which will act on a best efforts basis for sales on Nasdaq and other permitted methods.
The company will pay TD Cowen a commission of up to 3.0% of gross proceeds and may start, pause, or terminate sales at its discretion. Separately, Kymera filed a resale prospectus supplement registering the potential resale by certain existing investors of up to 18,819,826 outstanding common shares and 12,565,253 shares issuable upon exercise of pre-funded warrants at an exercise price of $0.0001 per warrant. Kymera will not receive proceeds from any resale of these shares, and will receive cash only if the warrants are exercised for cash.
Kymera Therapeutics reported fourth-quarter and full-year 2025 results alongside a broad pipeline update. Collaboration revenue for 2025 was $39.2 million, down from $47.1 million in 2024, while higher R&D spending of $316.6 million and G&A of $68.2 million drove a wider annual net loss of $311.4 million versus $223.9 million a year earlier.
The company significantly strengthened its balance sheet by completing an underwritten equity offering with total gross proceeds of approximately $692 million, ending 2025 with about $1.6 billion in cash, cash equivalents and investments and projecting a cash runway into 2029.
Kymera highlighted progress for its KT-621 STAT6 degrader, including positive Phase 1b atopic dermatitis data, FDA Fast Track designation, and ongoing Phase 2b BROADEN2 (AD) and BREADTH (asthma) trials. It also began first-in-human dosing for KT-579, an IRF5 degrader in Phase 1, advanced partnered IRAK4 and CDK2 programs, and appointed experienced developer Neil Graham as Chief Development Officer.
Kymera Therapeutics, Inc. reported a preliminary estimate of approximately $1.6 billion in cash, cash equivalents and marketable securities as of December 31, 2025. These figures are unaudited, form part of its fourth-quarter and full-year 2025 results, and may change as the year-end audit is completed.
The company also provided a business update and outlined its key 2026 objectives and strategy to advance its leading portfolio of immunology programs in a press release furnished as Exhibit 99.1. Kymera plans to discuss these topics in meetings with participants at the 44th Annual J.P. Morgan Healthcare Conference.
Kymera Therapeutics, Inc. reported that it hosted a conference call on December 8, 2025 to discuss results from its BroADen Phase 1b atopic dermatitis patient trial of KT-621, described as a first-in-class, oral STAT6 degrader. The company furnished a related slide presentation as Exhibit 99.1, noting that this material is provided for informational purposes and is not deemed “filed” for liability under Section 18 of the Exchange Act or automatically incorporated into other securities filings. Kymera also stated it undertakes no obligation to update, supplement, or amend the slide materials.
Kymera Therapeutics, Inc. filed a current report to note that it announced its financial results for the quarter ended September 30, 2025. The company is furnishing, as an exhibit, a press release that provides details on its results of operations and financial condition for that quarter.
The report clarifies that the press release and related information are being furnished rather than filed under securities laws, which affects how they are treated for certain legal liability and incorporation-by-reference purposes.
Kymera Therapeutics, Inc. announced that Chief Legal Officer Ellen Chiniara, J.D. informed the company on August 27, 2025 of her intent to retire from the role, effective September 3, 2025. The company states that her retirement is not due to any disagreement regarding operations, policies, or practices, and she will not receive severance payments or benefits in connection with her departure.
Effective September 3, 2025, Brian R. Adams, J.D. will succeed Ms. Chiniara as Chief Legal Officer. The company also issued a press release on September 3, 2025 announcing the retirement and appointment, which is furnished as an exhibit to this report.
Kymera Therapeutics announced that it reported its financial results for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to a Current Report on Form 8-K. The filing states the press release is being furnished and not deemed "filed" under the Exchange Act, and the cover page includes interactive data.
The Form 8-K text does not include the underlying financial figures; readers are referred to the furnished press release for detailed results. The report is signed by Nello Mainolfi, Ph.D., President and Chief Executive Officer, confirming the submission of the exhibit.
Kymera Therapeutics (NASDAQ: KYMR) has entered into a definitive underwriting agreement for a sizeable follow-on equity offering. The company will issue 5,044,500 new common shares at $44.00 per share and 655,500 pre-funded warrants at $43.9999 per warrant, equivalent to the share price less the $0.0001 exercise price. Underwriters have a 30-day option to purchase up to 855,000 additional shares.
Gross proceeds could reach $272.7 million if the option is fully exercised; net proceeds are estimated at $237.3 million (or $272.7 million including the option) after fees and expenses. Management plans to deploy the capital to advance its protein-degrader pipeline, expand clinical programs, and for general corporate purposes. With existing cash plus the offering proceeds, Kymera projects a cash runway into mid-2028.
The pre-funded warrants are immediately exercisable, subject to ownership limits (initially 4.99 % or 9.99 %, adjustable up to 19.99 %). They will not be listed on any exchange. The company also executed a Registration Rights Agreement covering up to 27,963,945 shares held by affiliated funds (Baker Brothers, Atlas Venture, and BVF Partners), allowing resale registration requests beginning 28 Feb 2026.
Press releases announcing the launch and pricing were issued on 25-26 Jun 2025. The transaction strengthens liquidity but introduces dilution, as the new shares and warrant exercises could expand the share count by roughly 6.6 million (plus any over-allotment), representing a high-single-digit percentage of the current float.
Kymera Therapeutics (NASDAQ:KYMR) filed an 8-K disclosing the June 25 2025 annual shareholder meeting results. Shareholders re-elected Jeffrey Albers and Felix Baker as Class II directors, approved the non-binding advisory vote on executive compensation, and ratified Ernst & Young as the independent auditor for fiscal 2025. No additional matters were submitted.
Kymera Therapeutics (NASDAQ:KYMR) announced a significant update to its Sanofi collaboration regarding IRAK4-targeting drug candidates. Sanofi has selected KT-485/SAR447971, an oral IRAK4 inhibitor for immuno-inflammatory diseases, to advance into clinical studies. The company received a $20 million milestone payment in Q2 2025 and is eligible for up to $975 million in additional milestones. Notably, Sanofi will not advance KT-474 and has exercised its participation election right for the IRAK4 target under the existing collaboration agreement.
Kymera Therapeutics (NASDAQ:KYMR) announced a major licensing deal with Gilead Sciences to develop novel oral molecular glue CDK2 degraders for oncology treatments. The agreement includes potential payments of up to $750 million, comprising $85 million in upfront and option exercise payments, plus tiered royalties ranging from high single-digit to mid-teens on net sales.
Kymera will lead research activities for the CDK2 program, while Gilead gains global rights to develop, manufacture, and commercialize resulting products upon exercising its option. The collaboration targets breast cancer and other solid tumors, representing a significant expansion of Kymera's therapeutic pipeline.